Skip to main content
Premium Trial:

Request an Annual Quote

Danaher Offering €6.20B in Senior Notes

NEW YORK – Danaher announced Tuesday that its European subsidiary priced an offering of €6.2 billion ($6.83 billion) in senior notes due between 2026 and 2049.

The company will offer €1.25 billion of .2 percent senior notes due in 2026; €1.25 billion of .45 percent senior notes due in 2028; €1.75 billion of .75 percent senior notes due in 2031; €1.25 billion of 1.35 percent senior notes due in 2039; and €750 million of 1.8 percent senior notes due in 2049.

The Washington, DC-based conglomerate said in a statement it plans to use the money to fund part of the cash consideration and other costs associated with its planned $21.4 billion acquisition of GE Life Sciences' Biopharma business. Danaher also said it may invest the proceeds in short-term bank deposits or investment-grade securities.

The company expects the offering to close on Sept. 18, 2019.

The Scan

Panel Recommends Pfizer-BioNTech Vaccine for Kids

CNN reports that the US Food and Drug Administration advisory panel has voted in favor of authorizing the Pfizer-BioNTech SARS-CoV-2 vaccine for children between 5 and 11 years old.

Sharing How to Make It

Merck had granted a royalty-free license for its COVID-19 treatment to the Medicines Patent Pool, according to the New York Times.

Bring it Back In

Bloomberg reports that a genetic analysis has tied a cluster of melioidosis cases in the US to a now-recalled aromatherapy spray.

Nucleic Acids Research Papers on SomaMutDB, VThunter, SCovid Databases

In Nucleic Acids Research this week: database of somatic mutations in normal tissue, viral receptor-related expression signatures, and more.